- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| Di | AROA BIOSURGERY LIMITED: Eligible NZ Employees Issued with ARX Shares | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| Mo | AROA BIOSURGERY LIMITED: AROA Business Update Presentation | - | ASX | ||
| Mo | AROA BIOSURGERY LIMITED: AROA Business Update | - | ASX | ||
| 27.01. | AROA BIOSURGERY LIMITED: Notification of Investor Webinar | - | ASX | ||
| 22.01. | AROA BIOSURGERY LIMITED: Study Demonstrates Effectiveness & Economic Value of Myriad | 1 | ASX | ||
| 09.01. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 18.12.25 | AROA BIOSURGERY LIMITED: Symphony Outpatient Reimbursement Update | - | ASX | ||
| 17.12.25 | Multi-channel sales strategy drives growth for tissue repair biotech Aroa | 7 | Stockhead | ||
| 25.11.25 | Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26 | 1 | smallcaps.com.au | ||
| 25.11.25 | Health Check: It's quarterly report 'Liberation Day' for Aroa after a bumper first half result | 1 | Stockhead | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Half Year Results Presentation | - | ASX | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 FY26 Results | - | ASX | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Appendix 4D and Half Year Report | - | ASX | ||
| 12.11.25 | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | 2 | ASX | ||
| 11.11.25 | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 Results Webinar & Investor Event | - | ASX | ||
| 03.11.25 | AROA BIOSURGERY LIMITED: Initial Director's Interest Notice - PS | - | ASX | ||
| 03.11.25 | AROA BIOSURGERY LIMITED: Final Director's Interest Notice - JP | - | ASX | ||
| 31.10.25 | AROA BIOSURGERY LIMITED: Paul Shearer to join Aroa Board and John Pinion to Retire | 1 | ASX | ||
| 15.10.25 | AROA BIOSURGERY LIMITED: Investor Presentation | - | ASX |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | |
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,910 | 0,00 % | HEIDELBERG PHARMA AG zeigt klare Stärke im Trend | ||
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| TREVENA | 4,000 | +1.983 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| DYNAVAX | 13,085 | -0,19 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,320 | +0,28 % | Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts | ||
| IBIO | 1,740 | -14,71 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,150 | -3,37 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| GALAPAGOS NV | 28,120 | -2,97 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,100 | +9,93 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen AROA BIOSURGERY LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.